MORPHOSYS AND JAPANESE PHARMACEUTICAL GROUP DAIICHI SANKYO FORM BROAD ALLIANCE TO DEVELOP NOVEL ANTIBODY THERAPIES

A A

MorphoSys AG today announced that Sankyo Company, Limited, a wholly owned subsidiary of Daiichi Sankyo Company, Limited, and MorphoSys AG have entered into a license agreement and therapeutic antibody collaboration for an initial two-year term with the option of an extension of up to three more years.

WebWire (http://www.webwire.com/ViewPressRel.asp?aId=11106)